Medicxi Ventures

Medicxi invests across the full venture lifecycle in healthcare. Its stated strategy covers early-stage science — seed and Series A biotech platforms — through to late-stage, expansion-capital rounds for clinical-stage drug developers, medical-device companies, and diagnostic firms.

Medicxi maintains three offices: a London headquarters for investment and operations, a Swiss office providing access to the Zurich-Geneva life-science corridor, and a Jersey office that likely serves as the fund domicile for limited-partner tax efficiency. This three-jurisdiction model is a common architecture for European venture managers.

Medicxi pursues direct venture investments — writing equity cheques into individual healthcare companies rather than allocating capital to other managers. The firm lists both investment and operations teams, suggesting it takes an active, hands-on approach to portfolio construction rather than farming out manager selection.

Medicxi targets three primary healthcare verticals: drug-development platforms, medical devices, and diagnostics. The firm does not currently tag any sector exclusions or negative screens on its public-facing materials, but its focus appears strictly within life sciences rather than broader healthcare services, payer models, or health IT.

No. Medicxi does not publish an AUM figure, fund-close amount, or total capital-deployment number on its website or in accessible public records. Its scale of operation is not independently verifiable.